Nonsteroidal Anti-Inflammatory Drugs Reduce Second Cancer Risk in Patients With Breast Cancer: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan

Frontiers in Oncology

Yin-Che Lu¹  Shi-Heng Wang³  Pin-Tzu Chen⁴  Yi-Jiun Pan⁶  Mei-Chen Lin⁶  Che-Chen Lin⁶ 

[1] Department of Nursing, Min-Hwei Junior College of Health Care Management, Tainan, Taiwan;Department of Occupational Safety and Health, China Medical University, Taichung, Taiwan;Department of Public Health, China Medical University, Taichung, Taiwan;Division of Hematology–Oncology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan;Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan;School of Medicine, China Medical University, Taichung, Taiwan;

关键词: NSAID;    breast cancer;    second cancer;    cohort study;    risk reduction;   

DOI  :  10.3389/fonc.2021.756143

来源: DOAJ

【 摘 要 】

Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce mortality in patients with cancer, especially breast cancer, but their influence on second cancer risk is uncertain. This study aimed to examine whether NSAID use is associated with second cancer risk in patients with breast cancer. This population-based propensity score-matched cohort study using Taiwan’s National Health Insurance Research Database enrolled patients with newly diagnosed breast cancer (n = 7356) with and without (n = 1839) NSAID therapy from 2000 to 2009. They were followed up until the diagnosis of second cancer, death, or end of 2011. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR). The NSAID cohort had a lower incidence rate of second cancer than the non-NSAID cohort (5.57 vs. 9.19 per 1,000 person-years), with an aHR of 0.63 (95% confidence interval (CI) 0.46–0.87). When compared with the non-NSAID cohort, the second cancer incidence was lower in patients taking non-cyclooxygenase 2 inhibitors (aHR 0.67, 95% CI 0.47–0.94) and in those receiving multiple NSAIDs during follow-up (aHR 0.55, 95% CI 0.37–0.84). A dose–response relationship existed in NSAID cumulative days. The findings demonstrate that NSAID use reduces second cancer risk in a dose-dependent manner in patients with primary breast cancer.

【 授权许可】

Unknown